Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RICI HEALTHCARE HOLDINGS LIMITED

瑞慈醫療服務控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 1526)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY CONTROLLING SHAREHOLDER

This announcement is made by Rici Healthcare Holdings Limited (the "**Company**") on a voluntary basis.

The board of directors (the "**Board**") of the Company was informed by Chelsea Grace Holdings Limited ("**Chelsea Grace**"), a controlling shareholder of the Company which is in turn directly wholly owned by Dr. Mei Hong, an executive director and controlling shareholder of the Company, that Chelsea Grace completed the acquisition of an aggregate of 268,286,800 shares of the Company (the "**Shares**") from Renaissance Healthcare Holdings Limited at a price of HK\$0.5 per Share on December 21, 2023 (the "**Acquisition**"). Immediately after the completion of the Acquisition, Chelsea Grace held an aggregate of 1,140,836,800 Shares, representing approximately 71.74% of the total issued share capital of the Company as at the date of this announcement.

As advised by Chelsea Grace, the Acquisition reflects its unswerving confidence in the future prospects and long-term development of the Company.

Based on the information available to the Company and to the knowledge of the Board, the Company has maintained sufficient public float as at the date of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board of **Rici Healthcare Holdings Limited Fang Yixin** *Chairman and Chief Executive Officer*

Shanghai, the PRC, December 21, 2023

As at the date of this announcement, the Board comprises four executive directors, namely Dr. Fang Yixin, Dr. Mei Hong, Mr. Fang Haoze and Ms. Lin Xiaoying; and three independent non-executive directors, namely Dr. Wang Yong, Mr. Jiang Peixing and Ms. Wong Sze Wing.